Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SYBX 
Synlogic Inc (SYBX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: SYBX (1-star) is a SELL. SELL since 2 days. Simulated Profits (32.23%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1
1 Year Target Price $1
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 5.13% | Avg. Invested days 39 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.72M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 1 | Beta 0.35 | 52 Weeks Range 0.90 - 1.96 | Updated Date 11/5/2025 |
52 Weeks Range 0.90 - 1.96 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -11.18% | Return on Equity (TTM) -7.3% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 911173 | Price to Sales(TTM) 1652.07 |
Enterprise Value 911173 | Price to Sales(TTM) 1652.07 | ||
Enterprise Value to Revenue 0.35 | Enterprise Value to EBITDA 0.18 | Shares Outstanding 11698919 | Shares Floating 3605724 |
Shares Outstanding 11698919 | Shares Floating 3605724 | ||
Percent Insiders 11.25 | Percent Institutions 64.65 |
Upturn AI SWOT
Synlogic Inc
Company Overview
History and Background
Synlogic, Inc. was founded in 2014, pioneering the field of Synthetic Biotics. They focus on developing living medicines to treat diseases. Key milestones include advancing multiple Synthetic Biotic medicines into clinical trials and establishing strategic partnerships.
Core Business Areas
- Therapeutic Development: Focuses on designing and developing Synthetic Biotic medicines for various metabolic and immunological diseases.
- Research and Discovery: Dedicated to identifying and developing new Synthetic Biotic platforms and applications.
- Manufacturing: Developing capabilities for the manufacturing of Synthetic Biotic medicines for clinical trials and potential commercialization.
Leadership and Structure
Aoife Brennan, M.B Ch.B., Ph.D., is the President and CEO. The company has a board of directors overseeing strategic direction. The organizational structure is divided into research, development, clinical, manufacturing, and administrative functions.
Top Products and Market Share
Key Offerings
- SYNB1618: An investigational Synthetic Biotic medicine for Phenylketonuria (PKU). Currently in clinical trials. No market share information available as it is not yet approved. Competitors include pharmaceutical companies with enzyme replacement therapies or gene therapies for PKU, such as BioMarin Pharmaceutical Inc. (BMRN) with Kuvan and Palynziq, and future gene therapies.
- SYNB1934: An investigational Synthetic Biotic medicine for solid tumors. Currently in clinical trials. No market share information available as it is not yet approved. Competitors include pharmaceutical companies such as Roche (RHHBY) and Bristol-Myers Squibb (BMY) developing cancer immunotherapies, and other companies developing oncolytic viruses and cell therapies.
Market Dynamics
Industry Overview
The synthetic biology and biotherapeutics market is rapidly growing, driven by advancements in genetic engineering and the increasing demand for novel therapies for various diseases. The market is competitive, with numerous companies developing innovative biotechnological solutions.
Positioning
Synlogic is a pioneer in the Synthetic Biotic field, focusing on using engineered bacteria to treat diseases. Their competitive advantage lies in their proprietary platform technology and expertise in designing Synthetic Biotic medicines.
Total Addressable Market (TAM)
The TAM for Synthetic Biotic medicines targeting metabolic and immunological diseases is estimated to be billions of dollars. Synlogic is positioned to capture a portion of this market with successful development and commercialization of their product candidates.
Upturn SWOT Analysis
Strengths
- Pioneering Synthetic Biotic platform technology
- Strong intellectual property portfolio
- Experienced management team
- Multiple product candidates in clinical development
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Clinical trial execution risk
- Dependence on regulatory approvals
- Unproven commercialization capabilities
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of Synthetic Biotic platform to new therapeutic areas
- Positive clinical trial results
- Advancements in manufacturing technologies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Unfavorable clinical trial outcomes
- Emergence of alternative technologies
Competitors and Market Share
Key Competitors
- BMRI
- RHHBY
- BMY
Competitive Landscape
Synlogic faces competition from larger pharmaceutical companies with established drug development and commercialization capabilities. Synlogic's advantage lies in its unique Synthetic Biotic platform. However, they are behind the others in revenue and profitability.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by the advancement of the product pipeline and strategic partnerships, rather than revenue. Synlogic has steadily progressed its Synthetic Biotic platform and clinical programs.
Future Projections: Future growth depends on the successful completion of clinical trials and potential regulatory approvals. Analyst estimates vary based on the perceived probability of success for Synlogic's product candidates.
Recent Initiatives: Recent initiatives include advancing clinical trials for SYNB1618 and SYNB1934, securing strategic collaborations, and expanding the Synthetic Biotic platform.
Summary
Synlogic, Inc. is an early-stage biotechnology company pioneering Synthetic Biotic medicines. Its success hinges on positive clinical trial outcomes and strategic partnerships. The company is reliant on financial support and regulatory approvals, and faces competition from more established pharmaceutical giants. The company needs to continue executing flawlessly on its product pipeline in order to justify investor support.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Synlogic Inc. Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
The data and analysis provided are for informational purposes only and do not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share estimations are approximations and may not reflect precise figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Synlogic Inc
Exchange NASDAQ | Headquaters Winchester, MA, United States | ||
IPO Launch date 2015-10-01 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.synlogictx.com |
Full time employees 1 | Website https://www.synlogictx.com | ||
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.